USP2

Ubiquitin carboxyl-terminal hydrolase 2 · O75604 · USP2 on Sugi Atlas →

1,034,071 patent compounds predicted against USP2, 671,606 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5531	0.50	12/20
SCHEMBL4015	0.73	9/20
Methacycline (SCHEMBL4014)	0.70	9/20
Methacycline (SCHEMBL4016)	0.70	9/20
SCHEMBL3446	0.62	8/20
Meclocycline (SCHEMBL3445)	0.59	8/20
Alclometasone Dipropionate (SCHEMBL6833)	1.00	7/20
Oxytetracycline (SCHEMBL2898)	0.70	7/20
Oxytetracycline (SCHEMBL2899)	0.70	7/20
Beclomethasone Dipropionate (SCHEMBL5095)	1.00	6/20
Beclomethasone Dipropionate (SCHEMBL6890)	1.00	6/20
Beclomethasone Dipropionate (SCHEMBL7329)	0.95	6/20
Doxycycline Anhydrous (SCHEMBL3156)	0.70	6/20
Doxycycline Anhydrous (SCHEMBL3155)	0.69	6/20
Rodorubicin (SCHEMBL8693)	0.58	6/20
SCHEMBL5264	0.46	6/20
Daunorubicin (SCHEMBL3041)	1.00	5/20
Clobetasol Propionate (SCHEMBL3997)	1.00	5/20
Daunorubicin (SCHEMBL4444)	1.00	5/20
Daunorubicin (SCHEMBL4445)	1.00	5/20

Clinical trials — most relevant to USP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer	PHASE2	COMPLETED
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Neuronal and Glial Biomarkers in Stroke	nan	COMPLETED
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis	nan	NOT_YET_RECRUITING
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a USP2 binder may also engage these)

Protein	Name	Similarity
Q2KHV7	—	1.000	Q2KHV7 →
Q5U349	—	0.999	Q5U349 →
O88623	—	0.998	O88623 →
Q80U87	—	0.982	Q80U87 →
B2GUZ1	—	0.982	B2GUZ1 →
Q9Y4E8	—	0.982	Q9Y4E8 →
USP4	Ubiquitin carboxyl-terminal hydrolase 4	0.981	landscape →
A6QR55	—	0.981	A6QR55 →
Q5RCD3	—	0.981	Q5RCD3 →
Q9C585	—	0.981	Q9C585 →
P35123	—	0.980	P35123 →
Q93Y01	—	0.980	Q93Y01 →
Q19469	—	0.979	Q19469 →
B3M301	—	0.979	B3M301 →
P24610	—	0.978	P24610 →
Q9MAQ3	—	0.978	Q9MAQ3 →
Q8R5H1	—	0.978	Q8R5H1 →
F6Z5C0	—	0.978	F6Z5C0 →
B4NBP4	—	0.978	B4NBP4 →
Q5SN53	—	0.977	Q5SN53 →
DCLK1	Serine/threonine-protein kinase DCLK1	0.977	landscape →
O22207	—	0.977	O22207 →
USP8	Ubiquitin carboxyl-terminal hydrolase 8	0.977	landscape →
Q9HFS7	—	0.977	Q9HFS7 →
Q9JLM8	—	0.977	Q9JLM8 →
Q754R5	—	0.977	Q754R5 →
Q2HJE4	—	0.977	Q2HJE4 →
P25799	—	0.977	P25799 →
Q24574	—	0.977	Q24574 →
Q9R085	—	0.977	Q9R085 →